Company Overview: Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders.
Upcoming Presentations: Members of Alto's management team will present at various investor conferences, with live webcasts available on their website.
Precision Psychiatry Platform™: The company utilizes a platform that measures brain biomarkers through EEG activity and other assessments to identify patients likely to respond to their treatments.
Clinical Pipeline: Alto's pipeline includes drug candidates targeting bipolar depression, major depressive disorder, treatment-resistant depression, schizophrenia, and other mental health conditions.
ANRO
$17.1+Infinity%1D
Analyst Views on ANRO
Wall Street analysts forecast ANRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANRO is 30.71 USD with a low forecast of 15.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast ANRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANRO is 30.71 USD with a low forecast of 15.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 17.030
Low
15.00
Averages
30.71
High
50.00
Current: 17.030
Low
15.00
Averages
30.71
High
50.00
BTIG
Thomas Shrader
initiated
$27
2025-11-17
Reason
BTIG
Thomas Shrader
Price Target
$27
2025-11-17
initiated
Reason
BTIG analyst Thomas Shrader initiated coverage of Alto Neuroscience with a Buy rating and $27 price target. The company is focused on next-generation drugs in psychiatry, including major depressive disorder and treatment-resistant depression, the analyst tells investors in a research note. The firm says each of Alto's programs is supported by "innovative" biomarkers to define subgroups of patients most likely to respond to the specific mechanism of the drug. It sees "several near-term validating" data readouts for the company.
Baird
Outperform
maintain
$16 -> $22
2025-11-13
Reason
Baird
Price Target
$16 -> $22
2025-11-13
maintain
Outperform
Reason
Baird raised the firm's price target on Alto Neuroscience to $22 from $16 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results which suggests clinical progress continues ahead of a catalyst-rich 2026.
Jefferies
Andrew Tsai
Buy
upgrade
$15 -> $25
2025-11-12
Reason
Jefferies
Andrew Tsai
Price Target
$15 -> $25
2025-11-12
upgrade
Buy
Reason
Jefferies analyst Andrew Tsai raised the firm's price target on Alto Neuroscience to $25 from $15 and keeps a Buy rating on the shares. Investor confidence in Alto's precision psychiatry approach could rise in 2026 as ALTO-101 has Phase II data in Q1 2026 for CIAS, ALTO-300 has full Phase IIb data in mid-2026 in MDD depression, ALTO-100 has Phase IIa data in BPD depression in the second half of 2026, and as investors seem most keen on ALTO-207, whose Phase IIb timelines were recently accelerated.
H.C. Wainwright
NULL -> Buy
upgrade
$10 -> $50
2025-10-24
Reason
H.C. Wainwright
Price Target
$10 -> $50
2025-10-24
upgrade
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on Alto Neuroscience to $50 from $10 and keeps a Buy rating on the shares. The firm incorporated the potential value from ALTO-207 in treatment-resistant depression into the company's model. The target increase reflects ALTO-207's blockbuster potential in TRD along with Alto's announced financing and "clear" regulatory path, the analyst tells investors in a research note.
About ANRO
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
